H.C. Wainwright raised the firm’s price target on vTv Therapeutics (VTVT) to $47 from $36 and keeps a Buy rating on the shares to reflect higher conviction in the long-term potential of cadisegliatin for Type 1 diabetes. The firm now models 25% peak market penetration, up from 20% previously, the analyst noted.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi
- Positive Outlook for vTv Therapeutics: Buy Rating on Cadisegliatin’s Promising Phase 3 Trial and Market Potential
- vTv Therapeutics initiated with a Buy at BTIG
- Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
- vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)